FundedIQ
Biotechnology

Visgenx: Funding, Investors & Team (Sep 2026)

Visgenx focuses on creating treatments to safeguard against vision impairment caused by retinal disorders. The company's initiatives revolve around enhancing the activity of a particular gene called ELOVL2, which has the potential to regulate the aging process in cells crucial for maintaining proper vision.

visgenx.com San Diego, United States 1-10 employees
Biotechnology Medical Therapeutics
Total raised
$2.8M
Rounds
1
Latest
Undisclosed round
Jun 2023

Visgenx has raised $2.8M across 1 funding round on record, the most recent an undisclosed round of $2.8M announced in Jun 2023.

That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Visgenx Company Profile and Key Stats

Total funding raised
$2.8M
across 1 round on record
Funding rounds on record
1
Latest funding round
Undisclosed round
$2.8M in Jun 2023
Employees
1-10
reported band
Headquarters
San Diego, United States

Latest funding round on record: Jun 2023.

Visgenx Funding Rounds

Date
Round
Amount
Undisclosed round
$2.8M

Visgenx Founders and Leadership Team

Name
Role
Contact
Daniel L Chao
Founder

No contact details are on record for this team yet.

Visgenx Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
29,795
$7.5M

Visgenx's latest round of $2.8M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Visgenx in Biotechnology and San Diego

Companies Similar to Visgenx

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…

Series A $35.0M

Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…

Convertible Note $3.5M

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

Visgenx Funding FAQs

What does Visgenx do?

Visgenx focuses on creating treatments to safeguard against vision impairment caused by retinal disorders. The company's initiatives revolve around enhancing the activity of a particular gene called ELOVL2, which has the potential to regulate the aging process in cells crucial for maintaining proper vision.

How much funding has Visgenx raised?

Visgenx has raised $2.8M across 1 round on record. The most recent is an undisclosed round of $2.8M announced in Jun 2023.

When did Visgenx last raise funding?

Visgenx's most recent funding round on record is an undisclosed round of $2.8M, announced in Jun 2023.

Who founded Visgenx?

FundedIQ lists Daniel L Chao (Founder) at Visgenx.

Where is Visgenx headquartered?

Visgenx is based in San Diego, California, United States.

How many employees does Visgenx have?

Visgenx is in the 1-10 employee band.

How does Visgenx's funding compare to other Biotechnology startups?

Visgenx's latest round of $2.8M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's Visgenx Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Visgenx is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.